The type and incidence of malignancy in 1500 renal transplant recipients at Kangnam St. Mary's Hospital.
- Author:
Jin Young KIM
1
;
Jennifer LEE
;
Sung Eun LEE
;
Su Hyun KIM
;
Bum Soon CHOI
;
In Sung MOON
;
Chul Woo YANG
;
Yong Soo KIM
;
Yong Bok KOH
;
Byung Kee BANG
Author Information
1. Department of Internal Medicine, Kangnam St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea. yangch@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Kidney transplantation;
Malignancy;
Incidence
- MeSH:
Azathioprine;
Carcinoma, Renal Cell;
Cervix Uteri;
Cyclosporine;
Diagnosis;
Female;
Follow-Up Studies;
Humans;
Immunosuppressive Agents;
Incidence*;
Kidney;
Kidney Transplantation;
Lymphoma;
Male;
Mass Screening;
Prognosis;
Retrospective Studies;
Sarcoma, Kaposi;
Stomach Neoplasms;
Tacrolimus;
Thyroid Neoplasms;
Transplantation*;
Transplants
- From:Korean Journal of Medicine
2007;73(1):67-75
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Strong immunosuppressive regimens have steadily improved both graft and patient survival, but posttransplant malignancy is still a clinical issue that needs to be resolved. METHODS: There were 1,500 transplant recipients between 1969 and 2005 at Kangnam St. Mary's hospital. The mean follow-up period was 108 77 months. We retrospectively analyzed the incidence, clinical course, treatment and prognosis of malignancy in the kidney transplant recipients. RESULTS: The incidence of malignancy after transplantation was 7.0% (10.5 cases out of 103 patients). The incidence of malignant lymphoma, thyroid cancer, renal cell carcinoma and Kaposi's sarcoma were higher in the renal transplanted patients than in the general population. The cancer incidence for women was higher than that for men, with stomach cancer being the most common in males and uterine cervix cancer the most common in females. The cumulative incidence of posttransplant malignancy at 1990, 1995, 2000 and 2005 were 0.72%, 2.91%, 4.62% and 7.0%, respectively. The cancer incidence with the use of initial immunosuppressive agents was 8.3% for azathioprine, 7.6% for cyclosporine, and 3.4% for tacrolimus. The mean times for making the diagnosis of malignancy after transplantation were 172+/-61 months for azathioprine, 91+/-49 months for cyclosporine, and 57+/-28 months for tacrolimus, respectively. During the observational period, 37 patients died (21 patients died of cancer) and 51 patients were still alive (7 grafts failed). CONCLUSIONS: The incidence of malignancy after renal transplantation increases according to the longer follow-up period. An active screening program is needed to lower the incidence of malignancy in renal transplant recipients.
